These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 30205701)

  • 41. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].
    Li R; Li WL; Yuan GS; Pang HJ; Li Q; Hu XY; Guo YB; Chen JZ; Zang MY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1163-1168. PubMed ID: 38238949
    [No Abstract]   [Full Text] [Related]  

  • 42. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
    Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Michitaka K; Deguchi A; Ishikawa T; Imai M; Ochi H; Joko K; Shimada N; Tajiri K; Hirooka M; Koizumi Y; Hiasa Y; Tanaka J
    J Gastroenterol Hepatol; 2019 Jun; 34(6):1066-1073. PubMed ID: 30549320
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
    Shin BS; Park MH; Jeon GS
    Acta Radiol; 2011 Apr; 52(3):331-5. PubMed ID: 21498371
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.
    Miki I; Murata S; Uchiyama F; Yasui D; Ueda T; Sugihara F; Saito H; Yamaguchi H; Murakami R; Kawamoto C; Uchida E; Kumita SI
    World J Gastroenterol; 2017 Sep; 23(35):6437-6447. PubMed ID: 29085193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
    Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma.
    Wang Z; Fan Q; Wang M; Wang E; Li H; Liu L
    Ann Transl Med; 2020 Apr; 8(8):537. PubMed ID: 32411760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
    Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
    J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma.
    Chan AW; Kumada T; Toyoda H; Tada T; Chong CC; Mo FK; Yeo W; Johnson PJ; Lai PB; Chan AT; To KF; Chan SL
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1300-6. PubMed ID: 26751608
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Albumin-bilirubin and platelet-albumin-bilirubin grades for hepatitis B-associated hepatocellular carcinoma in Child-Pugh A patients treated with radical surgery: A retrospective observational study.
    Wu B; Hu X; Jin H; Zhou L; Zhang D; Man Z; Wang Y; Yang S; Pang Q; Liu H; Cui P
    Medicine (Baltimore); 2019 Oct; 98(43):e17394. PubMed ID: 31651841
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients.
    Park KH; Kim JH; Choe WH; Kwon SY; Yoo BC; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
    Korean J Gastroenterol; 2020 Mar; 75(3):147-156. PubMed ID: 32209803
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function.
    Hsu KF; Chu CH; Chan DC; Yu JC; Shih ML; Hsieh HF; Hsieh TY; Yu CY; Hsieh CB
    Eur J Radiol; 2012 Mar; 81(3):466-71. PubMed ID: 21376495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade.
    Hiraoka A; Kumada T; Nouso K; Tsuji K; Itobayashi E; Hirooka M; Kariyama K; Ishikawa T; Tada T; Toyoda H; Kawasaki H; Hiasa Y; Michitaka K
    Oncology; 2016; 91(3):153-61. PubMed ID: 27362669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proposal of a New Preoperative Prognostic Model for Solitary Hepatocellular Carcinoma Incorporating
    Yoh T; Seo S; Ogiso S; Kawai T; Okuda Y; Ishii T; Taura K; Higashi T; Nakamoto Y; Hatano E; Kaido T; Uemoto S
    Ann Surg Oncol; 2018 Feb; 25(2):542-549. PubMed ID: 29168098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment.
    Hu K; Yuan J; Tang B; Zhang F; Lu S; Chen R; Zhang L; Ren Z; Yin X
    Ann Transl Med; 2021 Feb; 9(3):237. PubMed ID: 33708864
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy.
    Gkika E; Bettinger D; Krafft L; Schultheiss M; Neeff HP; Maruschke L; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
    Strahlenther Onkol; 2018 May; 194(5):403-413. PubMed ID: 29322205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma.
    Shen PC; Chang WC; Lo CH; Yang JF; Lee MS; Dai YH; Lin CS; Fan CY; Huang WY
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):307-318. PubMed ID: 31175903
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An Albumin-Bilirubin (ALBI) Grade-based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria.
    Ho SY; Liu PH; Hsu CY; Hsia CY; Su CW; Huang YH; Lei HJ; He YJ; Hou MC; Huo TI
    Am J Clin Oncol; 2019 Sep; 42(9):698-704. PubMed ID: 31335351
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intra arterial treatment of hepatocellular carcinoma: Comparison of MELD score variations between radio-embolization and chemo-embolization.
    Delicque J; Hermida M; Piron L; Allimant C; Belgour A; Pageaux GP; Ben Bouallegue F; Assenat E; Mariano-Goulart D; Guiu B; Cassinotto C
    Diagn Interv Imaging; 2019 Nov; 100(11):689-697. PubMed ID: 31281074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma.
    Ho SY; Hsu CY; Liu PH; Hsia CY; Su CW; Huang YH; Hou MC; Huo TI
    Eur J Surg Oncol; 2019 May; 45(5):776-781. PubMed ID: 30401507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.